Kinase Chemistry – Just a year and a half behind the times.


Posted by kinasepro on January 11, 2007

Helluva week for Genentech

1) Partners up XL518

2) Makes Fortune’s #2

3) Boasts at JP Morgan: ‘We’ve got too much money’

4) Loses a Supreme Court decision vs. Medimmune

5) Submits year end 8k

6) Buys Amphora’s “unnamed” (AKT) program.

…Genentech will purchase Amphora’s entire program for an unnamed oncology target with the potential to treat multiple oncology indications. Other terms of the agreement were not disclosed.

Not partner mind you: purchase. Amphora’s most recent AKT application is WO/2006/020767. Chiron appears to have the closest AKT examples in WO/2005/095386 included for the helluvit.


>> UPDATE 5/1/07 >> Genentech is now listed as an applicant the Amphora application: WO/2006/020767. Other Amphora ‘ATP-Utilizing Enzyme Inhibitors: ‘WO/2005/033102 & WO/2005/097758 (same inventors)


2 Responses to “DNA WEEK”

  1. Does the Amphora Compound look like it competes for he ATP binding pocket?

  2. kinasepro said

    I think both of these compounds sit similarly to 2GU8 and that an ensuing Genentech application is bound to have a methylaminopyrimidine bound to the thiophene!
    But what do I know?

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: